Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development

Cancer Gene Therapy volume 16, pages 807–809 (2009)Cite this article

Abstract

This review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based therapeutics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.

    Article  CAS  Google Scholar 

  2. Macron D . Breakdown of RNAi-based drugs in the clinic. RNAi News 2008 (online publication at www.rnainews.com October 16, 2008).

  3. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268–274.

    Article  Google Scholar 

  4. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108–1113.

    Article  CAS  Google Scholar 

  5. Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A et al. Proof concept for clinical justification of network mapping for personalized cancer therapeutics. Cancer Gene Ther 2007; 14: 686–695.

    Article  CAS  Google Scholar 

  6. Bumcrot D, Manoharan M, Koteliansky V, Sah DW . RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711–719.

    Article  CAS  Google Scholar 

  7. Yew NS, Scheule RK . Toxicity of cationic lipid-DNA complexes. Adv Genet 2005; 53: 189–214.

    Article  CAS  Google Scholar 

  8. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537–541.

    Article  CAS  Google Scholar 

  9. Grimm D, Kay MA . Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117: 3633–3641.

    Article  CAS  Google Scholar 

  10. Giering JC, Grimm D, Storm TA, Kay MA . Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16: 1630–1636.

    Article  CAS  Google Scholar 

  11. Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K et al. Off-target effects by siRNA can induce toxic phenotype. RNA (New York, NY) 2006; 12: 1188–1196.

    Article  CAS  Google Scholar 

  12. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L et al. Widespread siRNA ‘off-target’ transcript silencing mediated by seed region sequence complementarity. RNA (New York, NY) 2006; 12: 1179–1187.

    Article  CAS  Google Scholar 

  13. Hoerter JA, Walter NG . Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA (New York, NY) 2007; 13: 1887–1893.

    Article  CAS  Google Scholar 

  14. Rao DD, Vorhies JS, Senzer N, Nemunaitis J . siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61: 746–759.

    Article  CAS  Google Scholar 

  15. Zeng Y, Cai X, Cullen BR . Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005; 392: 371–380.

    Article  CAS  Google Scholar 

  16. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37: 1289–1295.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gradalis Inc., Dallas, TX, USA

    D D Rao, N Senzer & J Nemunaitis

  2. Mary Crowley Cancer Research Centers, Dallas, TX, USA

    N Senzer & J Nemunaitis

  3. Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc, Seattle, WA, USA

    M A Cleary

Authors
  1. D D Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Senzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M A Cleary
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Nemunaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Nemunaitis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rao, D., Senzer, N., Cleary, M. et al. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 16, 807–809 (2009). https://doi.org/10.1038/cgt.2009.53

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2009.53

Keywords

This article is cited by

Search

Advanced search

Quick links